Myrbetriq Available for Overactive Bladder Treatment
Astellas Pharma announced that Myrbetriq (mirabegron) extended-release tablets, indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency, is now available.
Myrbetriq is a once-daily, oral beta-3 adrenergic agonist. Myrbetriq relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of beta-3 adrenergic receptors which increases bladder capacity.
Myrbetriq is available as 25mg and 50mg dosage strength extended-release tablets in 30- and 90-count bottles.
For more information call (800) 727-7003 or visit www.us.astellas.com.